Proximity-mediated rolling circle amplification

• US 20040248103A1
• Filed: 06/04/2003
• Published: 12/09/2004
• Est. Priority Date: 06/04/2003
• Status: Abandoned Application

• Current Assignee: Qiagen GmbH (Qiagen NV)
• Original Assignee: Qiagen GmbH (Qiagen NV)
• Inventors: Feaver, William John, Mullenix, Michael
• Application Number:
  US10/454,946
• Publication Number:
  US 20040248103A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C12Q 1/6804 Nucleic acid analysis using immunogens immunoassay G01N33/53
• CPC Class Codes: C12Q 2531/125 Rolling circle
• CPC Class Codes: C12Q 2533/107 Probe or oligonucleotide ligation
• CPC Class Codes: G01N 33/542 with steric inhibition or signal modification, e.g. fluorescent quenching

Abstract

Disclosed are compositions and methods for proximity-mediated rolling circle amplification and for real-time detection of proximity-mediated rolling circle amplification products. Rolling circle amplification (RCA) refers to nucleic acid amplification reactions involving replication of a circular nucleic acid template to form a long strand with tandem repeats of the sequence complementary to the circular template. In proximity-mediated RCA, binding guide conjugates are brought into close proximity, generally by associating them to the same analyte or to two analytes in close proximity. The binding guide conjugates comprise a specific binding molecule and a guide oligonucleotide. The guide oligonucleotides are complementary to guide complement portions on half circle probes. The complementary sequences between the guide oligonucleotides and half circle probes allow both ends of each half circle probe to hybridize adjacent to an end of the other half circle probe and to be ligated together to form a circular nucleic acid molecule comprising the two half circle probes. This circular nucleic acid molecule can then be used as the template in RCA.

Claims

1. A method comprising:

(a) bringing into contact one or more analyte samples and one or more binding guide conjugates, wherein each binding guide conjugate comprises a specific binding molecule and a guide oligonucleotide, wherein each specific binding molecule interacts directly or indirectly with an analyte in the analyte sample, and

incubating the analyte samples and the binding guide conjugates under conditions that promote interaction of the specific binding molecules and the analytes,

(b) prior to, simultaneous with, or following step (a), bringing into contact the binding guide conjugates and one or more half circle probes, wherein each half circle probe comprises a single-stranded DNA molecule comprising two guide complement portions, wherein each guide complement portion is complementary to one of the guide oligonucleotides, and

incubating the binding guide conjugates and the half circle probes under conditions that promote hybridization between the guide oligonucleotides and the half circle probes,

(c) following step (b) and prior to, simultaneous with, or following step (a), incubating the binding guide conjugates and half circle probes under conditions that promote ligation of half circle probes, thereby producing one or more amplification target circles.

2. The method of claim 1, wherein hybridization between the guide oligonucleotides and the half circle probes results in one or more pairs of half circle probes hybridized to one or more pairs of guide oligonucleotides.

3. The method of claim 2, wherein one or more amplification target circles are produced by ligation of the half circle probes in one or more of the pairs of half circle probes hybridized to pairs of guide oligonucleotides.

4. The method of claim 1, wherein each guide oligonucleotide is complementary to one of the guide complement portions of both half circle probes in a pair of half circle probes, wherein the guide complement portions of the same half circle probe are complementary to two different guide oligonucleotides,

wherein the two different guide oligonucleotides that each are complementary to a different one of the guide complement portions of the same half circle probe constitute a pair of guide oligonucleotides, wherein the binding guide conjugates that comprise the guide oligonucleotides in a pair of guide oligonucleotides constitute a pair of binding guide conjugates,

wherein one guide complement portion of each half circle probe in a pair of half circle probes is complementary to one of the guide oligonucleotides in a pair of guide oligonucleotides and the other guide complement portion of each half circle probe in the pair of half circle probes is complementary to the other guide oligonucleotide in the pair of guide oligonucleotides,

wherein the specific binding molecules of the binding guide conjugates in a pair of binding guide conjugates are in close proximity when interacting with the analytes, wherein both half circle probes in a pair of half circle probes are hybridized to both guide oligonucleotides in a pair of guide oligonucleotides, and

wherein the half circle probes in one or more pairs of half circle probes are ligated to each other to form the amplification target circles.

5. The method of claim 4, wherein both specific binding molecules of a pair of binding guide conjugates interact with the same analyte.

6. The method of claim 4, wherein both specific binding molecules of a pair of binding guide conjugates interact with different analytes in close proximity.

7. The method of claim 4, wherein both specific binding molecules of a pair of binding guide conjugates interact with different analytes on the same molecule.

8. The method of claim 4, wherein each guide oligonucleotide is complementary to one of the guide complement portions of both half circle probes in a different pair of half circle probes.

9. The method of claim 4, wherein the binding guide conjugates brought into contact with the analyte samples comprise a plurality of pairs of binding guide conjugates, wherein the guide oligonucleotides of the binding guide conjugates brought into contact with the analyte samples comprise a plurality of pairs of guide oligonucleotides, and wherein the half circle probes brought into contact with the binding guide conjugates comprise a plurality of pairs of half circle probes.

10. The method of claim 9, wherein both specific binding molecules of each pair of binding guide conjugates interact with the same analyte.

11. The method of claim 9, wherein both specific binding molecules of each pair of binding guide conjugates interact with different analytes in close proximity.

12. The method of claim 9, wherein both specific binding molecules of each pair of binding guide conjugates interact with different analytes on the same molecule.

13. The method of claim 9, wherein the specific binding molecules of each pair of binding guide conjugates do not interact with the same analyte as the specific binding molecules of any other pair binding guide conjugates.

14. The method of claim 9, wherein the specific binding molecules of one or more pairs of binding guide conjugates interact with the same analyte as the specific binding molecules of another pair binding guide conjugates.

15. The method of claim 9, wherein the half circle probes of each pair of half circle probes are hybridized to only one of the pairs of guide oligonucleotides.

16. The method of claim 9, wherein the half circle probes of each pair of half circle probes are hybridized to one or more of the pairs of guide oligonucleotides.

17. The method of claim 9, wherein one of the half circle probes of each pair of half circle probes is hybridized to only one of the pairs of guide oligonucleotides and the other half circle probe of each pair of half circle probes is hybridized to a plurality of the pairs of guide oligonucleotides.

18. The method of claim 9, wherein one of the half circle probes of each pair of half circle probes is hybridized to only one of the pairs of guide oligonucleotides and the other half circle probe of each pair of half circle probes is hybridized to all of the pairs of guide oligonucleotides.

19. The method of claim 9, wherein a plurality of amplification target circles are produced by ligation of a plurality of the pairs of half circle probes.

20. The method of claim 4, wherein the binding guide conjugates brought into contact with the analyte samples comprise a pair of binding guide conjugates, wherein the guide oligonucleotides of the binding guide conjugates brought into contact with the analyte samples comprise a pair of guide oligonucleotides, and wherein the half circle probes brought into contact with the binding guide conjugates comprise a pair of half circle probes.

21. The method of claim 4, wherein the half circle probes in a pair of half circle probes are sequentially brought into contact with the binding guide conjugates.

22. The method of claim 1, wherein each guide oligonucleotide is complementary to one of the guide complement portions of both half circle probes in a pair of half circle probes, wherein the guide complement portions of the same half circle probe are complementary to two different guide oligonucleotides,

wherein the two different guide oligonucleotides that each are complementary to a different one of the guide complement portions of the same half circle probe constitute a pair of guide oligonucleotides, wherein the binding guide conjugates that comprise the guide oligonucleotides in a pair of guide oligonucleotides constitute a pair of binding guide conjugates,

wherein one guide complement portion of each half circle probe in a pair of half circle probes is complementary to one of the guide oligonucleotides in a pair of guide oligonucleotides and the other guide complement portion of each half circle probe in the pair of half circle probes is complementary to the other guide oligonucleotide in the pair of guide oligonucleotides,

wherein the specific binding molecules interact with different analytes, wherein the specific binding molecule of one of the binding guide conjugates in a pair of binding guide conjugates interacts with an analyte in close proximity to the analyte that interacts with the specific binding molecule of the other binding guide conjugate in the pair of binding guide conjugates, wherein both half circle probes in a pair of half circle probes are hybridized to both guide oligonucleotides in a pair of guide oligonucleotides, and

wherein the half circle probes in a pair of half circle probes are ligated to each other to form an amplification target circle.

23. The method of claim 1, wherein the method further comprises, following step (c),

(d) incubating the amplification target circles under conditions that promote replication of the amplification target circles, wherein replication of the amplification target circles results in the formation of tandem sequence DNA.

24. The method of claim 23, wherein the method further comprises bringing into contact at least one of the analyte samples and one or more analyte capture agents, wherein each analyte capture agent interacts with an analyte directly or indirectly, wherein at least one analyte, if present in the analyte sample, interacts with at least one analyte capture agent,

wherein at least one analyte capture agent is associated with a solid support, wherein analytes that interact with the analyte capture agent associated with a solid support become associated with the solid support,

wherein each of the analyte capture agents is located in a different predefined region of the solid support, and

wherein the location of tandem sequence DNA on the solid support indicates the presence in the analyte sample of the analyte corresponding to the analyte capture agent at that location of the solid support.

25. The method of claim 23, wherein the method further comprises detecting the tandem sequence DNA.

26. The method of claim 25, wherein detection of tandem sequence DNA indicates the presence of the corresponding analytes.

27. The method of claim 25, wherein detection of the tandem sequence DNA is accomplished by mixing a set of detection probes with the tandem sequence DNA under conditions that promote hybridization between the tandem sequence DNA and the detection probes.

28. The method of claim 27, wherein a plurality of different tandem sequence DNAs are detected separately and simultaneously via multiplex detection.

29. The method of claim 28, wherein the set of detection probes is labeled using combinatorial multicolor coding.

30. The method of claim 23, further comprising, simultaneous with, or following, step (d),

bringing into contact a secondary DNA strand displacement primer and the tandem sequence DNA, and incubating under conditions that promote (i) hybridization between the tandem sequence DNA and the secondary DNA strand displacement primer, and (ii) replication of the tandem sequence DNA, wherein replication of the tandem sequence DNA results in the formation of secondary tandem sequence DNA.

31. The method of claim 1, wherein prior to, simultaneous with, or following steps (a), (b), or (c) the analytes are separated from the analyte samples.

32. The method of claim 31, wherein the analytes are separated from the analyte sample by bringing into contact at least one of the analyte samples and one or more analyte capture agents, wherein each analyte capture agent interacts with an analyte directly or indirectly, wherein at least one analyte, if present in the analyte sample, interacts with at least one analyte capture agent, and separating analyte capture agents from the analyte samples, thus separating analytes from the analyte samples.

33. The method of claim 1, wherein a plurality of binding guide conjugates are brought into contact with the one or more analyte samples.

34. The method of claim 1, wherein a plurality of analyte samples are brought into contact with the one or more binding guide conjugates.

35. The method of claim 1, wherein at least one of the analytes is a protein or peptide.

36. The method of claim 1, wherein at least one of the analytes is a lipid, glycolipid, or proteoglycan.

37. The method of claim 1, wherein at least one of the analytes is from a human source.

38. The method of claim 1, wherein at least one of the analytes is from a non-human source.

39. The method of claim 1, wherein none of the analytes are nucleic acids.

40. The method of claim 1, wherein at least one of the analyte samples and one or more analyte capture agents are brought into contact, wherein each analyte capture agent interacts with an analyte directly or indirectly, and wherein at least one analyte, if present in the analyte sample, interacts with at least one analyte capture agent.

41. The method of claim 40, wherein the analyte capture agents are separated from the analyte samples, thus separating analytes from the analyte samples.

42. The method of claim 40, wherein at least one analyte capture agent is associated with a solid support, and wherein analytes that interact with the analyte capture agent associated with a solid support become associated with the solid support.

43. The method of claim 42, wherein each of the analyte capture agents is located in a different predefined region of the solid support.

44. The method of claim 43, wherein the distance between the different predefined regions of the solid support is fixed.

45. The method of claim 44, wherein the solid support comprises thin film, membrane, bottles, dishes, fibers, woven fibers, shaped polymers, particles, beads, microparticles, or a combination.

46. The method of claim 43, wherein the distance between at least two of the different predefined regions of the solid support is variable.

47. The method of claim 46, wherein the solid support comprises at least one thin film, membrane, bottle, dish, fiber, woven fiber, shaped polymer, particle, bead, or microparticle.

48. The method of claim 47, wherein the solid support comprises at least two thin films, membranes, bottles, dishes, fibers, woven fibers, shaped polymers, particles, beads, microparticles, or a combination.

49. The method of claim 42, wherein the solid support comprises a plurality of analyte capture agents located in a plurality of different predefined regions of the solid support, wherein the analyte capture agents collectively correspond to a plurality of analytes.

50. The method of claim 42, wherein the solid support comprises thin film, membrane, bottles, dishes, fibers, woven fibers, shaped polymers, particles, beads, microparticles, or a combination.

51. The method of claim 42, wherein the solid support comprises acrylamide, agarose, cellulose, nitrocellulose, glass, polystyrene, polyethylene vinyl acetate, polypropylene, polymethacrylate, polyethylene, polyethylene oxide, polysilicates, polycarbonates, teflon, fluorocarbons, nylon, silicon rubber, polyanhydrides, polyglycolic acid, polylactic acid, polyorthoesters, polypropylfumerate, collagen, glycosaminoglycans, or polyamino acids.

52. The method of claim 42, wherein the solid support is porous.

53. The method of claim 40, further comprising bringing into contact at least one of the analyte samples and at least one of the binding guide conjugates with at least one accessory molecule, and wherein the accessory molecule affects the interaction of at least one of the analytes and at least one of the specific binding molecules or at least one of the analyte capture agents.

54. The method of claim 53, wherein the accessory molecule is brought into contact with at least one of the analyte samples, at least one of the binding guide conjugates, or both, prior to, simultaneous with, or following step (a).

55. The method of claim 53, wherein at least one analyte capture agent is associated with a solid support, and wherein the accessory molecule is associated with the solid support.

56. The method of claim 55, wherein the accessory molecule is associated with the solid support by bringing the accessory molecule into contact with the solid support prior to, simultaneous with, or following step (a).

57. The method of claim 53, wherein the accessory molecule is a protein kinase, a protein phosphatase, an enzyme, or a compound.

58. The method of claim 53, wherein the accessory molecule is a molecule of interest, wherein one or more of the analytes are test molecules, and wherein interactions of the test molecules with the molecule of interest are detected.

59. The method of claim 53, wherein at least one of the analytes is a molecule of interest, wherein the accessory molecule is a test molecule, and wherein interactions of the test molecule with the molecule of interest are detected.

60. The method of claim 40, wherein at least one of the analyte capture agents is a molecule of interest, wherein one or more of the analytes are test molecules, and wherein interactions of the test molecules with the molecule of interest are detected.

61. The method of claim 40, wherein at least one of the analytes is a molecule of interest, wherein one or more of the analyte capture agents are test molecules, and wherein interactions of the test molecules with the molecule of interest are detected.

62. The method of claim 1, wherein at least one of the specific binding molecules is an antibody specific for at least one of the analytes.

63. The method of claim 1, wherein at least one of the specific binding molecules is a molecule that specifically binds to at least one of the analytes.

64. The method of claim 1, wherein at least one of the specific binding molecules is a molecule that specifically binds to at least one of the analytes in combination with an accessory molecule.

65. The method of claim 1, wherein at least one accessory molecule is brought into contact with at least one of the analyte samples and at least one of the binding guide conjugates, and wherein the accessory molecule affects the interaction of at least one of the analytes and at least one of the specific binding molecules or at least one of the analyte capture agents.

66. The method of claim 65, wherein the accessory molecule competes with the interaction of at least one of the specific binding molecules or at least one of the analyte capture agents.

67. The method of claim 66, wherein the accessory molecule is an analog of at least one of the analytes.

68. The method of claim 65, wherein the accessory molecule facilitates the interaction of at least one of the specific binding molecules or at least one of the analyte capture agents.

69. The method of claim 65, wherein the accessory molecule is brought into contact with at least one of the analyte samples, at least one of the binding guide conjugates, or both, prior to, simultaneous with, or following step (a).

70. The method of claim 65, wherein the accessory molecule is a protein kinase, a protein phosphatase, an enzyme, or a compound.

71. The method of claim 65, wherein the accessory molecule is at least 20% pure.

72. The method of claim 65, wherein the accessory molecule is at least 50% pure.

73. The method of claim 65, wherein the accessory molecule is at least 80% pure.

74. The method of claim 65, wherein the accessory molecule is at least 90% pure.

75. The method of claim 1, wherein at least one of the analytes is associated with a solid support.

76. The method of claim 75, wherein each of the analytes associated with the solid support is associated with the solid support in a different predefined region.

77. The method of claim 75, wherein at least one of the analytes associated with the solid support is associated with the solid support indirectly.

78. The method of claim 77, wherein the analytes associated with the solid support interact with analyte capture agents, and wherein the analyte capture agents are associated with the solid support thereby indirectly associating the analytes with the solid support.

79. The method of claim 1, wherein at least one specific binding molecule interacts with at least one analyte indirectly.

80. The method of claim 79, wherein the analyte interacts with an analyte capture agent, and wherein the specific binding molecule interacts with the analyte capture agent thereby indirectly associating the specific binding molecule with the analyte.

81. The method of claim 1, wherein at least one of the analytes is a modified form of another analyte, wherein the specific binding molecule of at least one of the binding guide conjugates interacts, directly or indirectly, with the analyte that is a modified form of the other analyte, and wherein the specific binding molecule of another binding guide conjugate interacts, directly or indirectly, with the other analyte.

82. The method of claim 81, wherein the analytes are proteins, wherein the modification of the modified form of the other analyte is a post-translational modification.

83. The method of claim 82, wherein the modification is phosphorylation or glycosylation.

84. The method of claim 1, wherein the binding guide conjugates are at least 20% pure.

85. The method of claim 1, wherein the binding guide conjugates are at least 50% pure.

86. The method of claim 1, wherein the binding guide conjugates are at least 80% pure.

87. The method of claim 1, wherein the binding guide conjugates are at least 90% pure.

88. The method of claim 1, wherein the binding guide conjugates include one or more first binding guide conjugates and one or more second binding guide conjugates, wherein the half circle probes include one or more first half circle probes and one or more second half circle probes,

wherein each first binding guide conjugate corresponds to at least one of the second binding guide conjugates, wherein the specific binding molecules of the first binding guide conjugates interact with the same analyte as the specific binding molecule of the second binding guide conjugate to which the first binding guide conjugate corresponds,

wherein one guide compliment portion of the first half circle probes hybridizes to the guide oligonucleotide of the first binding guide conjugate and another guide compliment portion of the first half circle probe hybridizes to the guide oligonucleotide of the second binding guide conjugate,

wherein one guide compliment portion of the second half circle probe hybridizes to the guide oligonucleotide of the first binding guide conjugate and another guide compliment portion of the second half circle probe hybridizes to the guide oligonucleotide of the second binding guide conjugate, and

wherein the first and second half circle probes are ligated together to form the amplification target circle.

89. The method of claim 88, wherein the first and second half circle probes are sequentially brought into contact with the binding guide conjugates.

90. The method of claim 1, wherein the analyte samples include two or more analytes in close proximity, wherein the binding guide conjugates include one or more first binding guide conjugates and one or more second binding guide conjugates, wherein the half circle probes include one or more first half circle probes and one or more second half circle probes,

wherein each first binding guide conjugate corresponds to at least one of the second binding guide conjugates, wherein the specific binding molecule of the first binding guide conjugates interact with an analyte in close proximity to the analyte that the specific binding molecule of the second binding guide conjugate to which the first binding conjugate corresponds interacts with,

wherein one guide compliment portion of the first half circle probe hybridizes to the guide oligonucleotide of the first binding guide conjugate and another guide compliment portion of the first half circle probe hybridizes to the guide oligonucleotide of the second binding guide conjugate,

wherein one guide compliment portion of the second half circle probe hybridizes to the guide oligonucleotide of the first binding guide conjugate and another guide compliment portion of the second half circle probe hybridizes to the guide oligonucleotide of the second binding guide conjugate, and

wherein the first and second half circle probes are ligated together to form the amplification target circle.

91. The method of claim 1, wherein two guide complement portions of two different half circle probes hybridize to the guide oligonucleotides, wherein one of the guide complement portions has a 5′

end and the other guide complement portion has a 3′

end.

92. The method of claim 91, wherein the 5′

end and the 3′

end are immediately adjacent when the two guide complement portions are hybridized to the guide oligonucleotide.

93. The method of claim 91, wherein the 5′

end and the 3′

end are separated by a central region when the two guide complement portions are hybridized to the guide oligonucleotide.

94. The method of claim 93, wherein step (b) further comprises, prior to incubating, bringing one or more gap oligonucleotides into contact with the binding guide conjugates, wherein each gap oligonucleotide comprises a single-stranded, linear DNA molecule, wherein each gap oligonucleotide is complementary all or a portion of the central region, wherein the gap oligonucleotides complementary to the central region are incorporated into the amplification target circles.

95. A method comprising:

(a) bringing into contact one or more analyte samples and one or more arrays, wherein each array comprises a set of analyte capture agents, a set of accessory molecules, or both, wherein each analyte capture agent interacts with an analyte directly or indirectly,

(b) prior to, simultaneous with, or following step (a), bringing into contact one or more of the arrays and one or more binding guide conjugates, wherein each binding guide conjugate comprises a specific binding molecule and a guide oligonucleotide, wherein each specific binding molecule interacts directly or indirectly with an analyte in the analyte sample, and

incubating the analyte samples and the binding guide conjugates under conditions that promote interaction of the specific binding molecules and the analytes,

(c) prior to, simultaneous with, or following steps (a) or (b), bringing into contact the binding guide conjugates and one or more half circle probes, wherein each half circle probe comprises a single-stranded DNA molecule comprising two guide complement portions, wherein each guide complement portion is complementary to at least one of the guide oligonucleotides, and

incubating the binding guide conjugates and the half circle probes under conditions that promote hybridization between the guide oligonucleotides and the half circle probes,

(d) following step (c) and prior to, simultaneous with, or following steps (a) or (b), incubating the binding guide conjugates and half circle probes under conditions that promote ligation of half circle probes to each other, thereby producing one or more amplification target circles, and

(e) following step (d), incubating the amplification target circles under conditions that promote replication of the amplification target circles, wherein replication of the amplification target circles results in the formation of tandem sequence DNA.

96. The method of claim 95, wherein each array comprises a set of analyte capture agents, and wherein each analyte capture agent is immobilized on a solid support in a different predefined region of the solid support.

97. The method of claim 96, wherein the distance between the different predefined regions of the solid support is fixed.

98. The method of claim 97, wherein the solid support comprises thin film, membrane, bottles, dishes, fibers, woven fibers, shaped polymers, particles, beads, microparticles, or a combination.

99. The method of claim 96, wherein the distance between at least two of the different predefined regions of the solid support is variable.

100. The method of claim 96, wherein the analyte capture agents are immobilized to the solid support at a density exceeding 400 different analyte capture agents per cubic centimeter.

101. The method of claim 96, wherein the analyte capture agents are peptides.

102. The method of claim 101, wherein each of the different peptides is at least 4 amino acids in length.

103. The method of claim 102, wherein each different peptide is from about 4 to about 20 amino acids in length.

104. The method of claim 102, wherein each different peptide is at least 10 amino acids in length.

105. The method of claim 102, wherein each different peptide is at least 20 amino acids in length.

106. The method of claim 96, wherein at least one array comprises at least 1,000 different analyte capture agents immobilized on the solid support.

107. The method of claim 96, wherein at least one array comprises at least 10,000 different analyte capture agents immobilized on the solid support.

108. The method of claim 96, wherein at least one array comprises at least 100,000 different analyte capture agents immobilized on the solid support.

109. The method of claim 96, wherein at least one array comprises at least 1,000,000 different analyte capture agents immobilized on the solid support.

110. The method of claim 96, wherein each of the different predefined regions is physically separated from each other of the different regions.

111. The method of claim 96, wherein the solid support comprises thin film, membrane, bottles, dishes, fibers, woven fibers, shaped polymers, particles, beads, microparticles, or a combination.

112. The method of claim 96, wherein the solid support comprises acrylamide, agarose, cellulose, nitrocellulose, glass, polystyrene, polyethylene vinyl acetate, polypropylene, polymethacrylate, polyethylene, polyethylene oxide, polysilicates, polycarbonates, teflon, fluorocarbons, nylon, silicon rubber, polyanhydrides, polyglycolic acid, polylactic acid, polyorthoesters, polypropylfumerate, collagen, glycosaminoglycans, or polyamino acids.

113. The method of claim 96, wherein the solid support is porous.

114. The method of claim 96, wherein the analyte capture agents in the different predefined regions are at least 20% pure.

115. The method of claim 96, wherein the analyte capture agents in the different predefined regions are at least 50% pure.

116. The method of claim 96, wherein the analyte capture agents in the different predefined regions are at least 80% pure.

117. The method of claim 96, wherein the analyte capture agents in the different predefined regions are at least 90% pure.

118. A method comprising:

(a) treating one or more analyte samples so that one or more analytes are modified,

(b) prior to, simultaneous with, or following step (a), bringing into contact one or more of the analyte samples and one or more binding guide conjugates, wherein each binding guide conjugate comprises a specific binding molecule and a guide oligonucleotide, wherein each specific binding molecule interacts directly or indirectly with an analyte in the analyte sample, and

incubating the analyte samples and the binding guide conjugates under conditions that promote interaction of the specific binding molecules and the analytes,

(c) prior to, simultaneous with, or following steps (a) or (b), bringing into contact the binding guide conjugates and one or more half circle probes, wherein each half circle probe comprises a single-stranded DNA molecule comprising two guide complement portions, wherein each guide complement portion is complementary to at least one of the guide oligonucleotides, and

incubating the binding guide conjugates and the half circle probes under conditions that promote hybridization between the guide oligonucleotides and the half circle probes,

(d) following step (c) and prior to, simultaneous with, or following steps (a) or (b), incubating the binding guide conjugates and half circle probes under conditions that promote ligation of half circle probes to each other, thereby producing one or more amplification target circles, and

(e) following step (d), incubating the amplification target circles under conditions that promote replication of the amplification target circles, wherein replication of the amplification target circles results in the formation of tandem sequence DNA.

119. The method of claim 118, wherein all of the analytes are modified by associating a modifying group to the analytes, wherein the modifying group is the same for all of the analytes, wherein all of the specific binding molecules interact with the modifying group.

120. A method comprising:

(a) bringing into contact one or more analyte samples and one or more arrays, wherein each array comprises a set of analyte capture agents, a set of accessory molecules, or both, wherein each analyte capture agent interacts with an analyte directly or indirectly,

(b) prior to, simultaneous with, or following step (a), bringing into contact one or more of the analyte samples and one or more binding guide conjugates, wherein each binding guide conjugate comprises a specific binding molecule and a guide oligonucleotide, wherein each specific binding molecule interacts directly or indirectly with an analyte in the analyte sample, and

incubating the analyte samples and the binding guide conjugates under conditions that promote interaction of the specific binding molecules and the analytes,

(c) prior to, simultaneous with, or following steps (a) or (b), bringing into contact the binding guide conjugates and one or more half circle probes, wherein each half circle probe comprises a single-stranded DNA molecule comprising two guide complement portions, wherein each guide complement portion is complementary to at least one of the guide oligonucleotides, and

incubating the binding guide conjugates and the half circle probes under conditions that promote hybridization between the guide oligonucleotides and the half circle probes,

(d) following step (c) and prior to, simultaneous with, or following steps (a) or (b), incubating the binding guide conjugates and half circle probes under conditions that promote ligation of half circle probes to each other, thereby producing one or more amplification target circles, and

(e) following step (d), incubating the amplification target circles under conditions that promote replication of the amplification target circles, wherein replication of the amplification target circles results in the formation of tandem sequence DNA.

121. A kit comprising

(a) a plurality of binding guide conjugates, wherein each binding guide conjugates comprises a specific binding molecule and a guide oligonucleotide, wherein each specific binding molecule interacts with an analyte directly or indirectly, and

(b) a plurality of half circle probes, wherein each half circle probe comprises a single-stranded DNA molecule comprising two guide complement portions, wherein each guide complement portion is complementary to at least one of the guide oligonucleotides.

122. The kit of claim 121, wherein the kit further comprises a plurality of analyte capture agents, and wherein each analyte capture agent interacts with an analyte directly or indirectly

123. The kit of claim 122, wherein the analyte capture agents are associated with a solid support.

124. The kit of claim 121, wherein each guide oligonucleotide is complementary to one of the guide complement portions of both half circle probes in a pair of half circle probes, wherein the guide complement portions of the same half circle probe are complementary to two different guide oligonucleotides,

wherein the two different guide oligonucleotides that each are complementary to a different one of the guide complement portions of the same half circle probe constitute a pair of guide oligonucleotides, wherein the binding guide conjugates that comprise the guide oligonucleotides in a pair of guide oligonucleotides constitute a pair of binding guide conjugates,

wherein one guide complement portion of each half circle probe in a pair of half circle probes is complementary to one of the guide oligonucleotides in a pair of guide oligonucleotides and the other guide complement portion of each half circle probe in the pair of half circle probes is complementary to the other guide oligonucleotide in the pair of guide oligonucleotides,

wherein the specific binding molecules of the binding guide conjugates in a pair of binding guide conjugates interact with the same analyte, and wherein both half circle probes in a pair of half circle probes are hybridized to both guide oligonucleotides in a pair of guide oligonucleotides.

125. The kit of claim 124, wherein each guide oligonucleotide is complementary to one of the guide complement portions of both half circle probes in a different pair of half circle probes.

126. The kit of claim 124, wherein the binding guide conjugates comprise a plurality of pairs of binding guide conjugates, wherein the guide oligonucleotides of the binding guide conjugates comprise a plurality of pairs of guide oligonucleotides, and wherein the half circle probes comprise a plurality of pairs of half circle probes.

127. The kit of claim 124, wherein the binding guide conjugates comprise a pair of binding guide conjugates, wherein the guide oligonucleotides of the binding guide conjugates comprise a pair of guide oligonucleotides, and wherein the half circle probes comprise a pair of half circle probes.

128. A method comprising:

(a) bringing into contact one or more analyte samples and one or more binding half circle conjugates, wherein each binding half circle conjugate comprises a specific binding molecule and a half circle probe, wherein each specific binding molecule interacts directly or indirectly with an analyte in the analyte sample, and wherein each half circle probe comprises a single-stranded DNA molecule comprising two guide complement portions, and

incubating the analyte samples and the binding half circle conjugates under conditions that promote interaction of the specific binding molecules and the analytes,

(b) prior to, simultaneous with, or following step (a), bringing into contact the binding half circle conjugates and one or more guide oligonucleotides, wherein each guide oligonucleotide is complementary to at least one of the guide complement portions of the half circle probes, and

incubating the binding half circle conjugates and the guide oligonucleotides under conditions that promote hybridization between the guide oligonucleotides and the half circle probes,

(c) following step (b) and prior to, simultaneous with, or following step (a), incubating the binding half circle conjugates and guide oligonucleotides under conditions that promote ligation of half circle probes to each other, thereby producing one or more amplification target circles, and

(d) following step (c), incubating the amplification target circles under conditions that promote replication of the amplification target circles, wherein replication of the amplification target circles results in the formation of tandem sequence DNA.

129. The method of claim 128, wherein following step (c) and prior to or simultaneous with step (d) the amplification target circles are disassociated from the specific binding molecules.

130. The method of claim 129, wherein the amplification target circles are disassociated from the specific binding molecules by cleaving covalent bonds.

131. The method of claim 129, wherein the amplification target circles are disassociated from the specific binding molecules by treating the amplification target circles with a reducing agent.

132. The method of claim 129, wherein the amplification target circles are disassociated from the specific binding molecules by heating the amplification target circles.

133. The method of claim 128, wherein the half circle probes are tethered to the specific binding molecules.

134. The method of claim 128, wherein the half circle probes are covalently coupled to the specific binding molecules.

135. The method of claim 134, wherein the half circle probes are covalently coupled to the specific binding molecules via a cleavable linker.

136. A method comprising:

(a) bringing into contact one or more analyte samples and one or more binding guide conjugates, wherein each binding guide conjugate comprises a specific binding molecule and a guide oligonucleotide, wherein each specific binding molecule interacts directly or indirectly with an analyte in the analyte sample, and

incubating the analyte samples and the binding guide conjugates under conditions that promote interaction of the specific binding molecules and the analytes,

(b) prior to, simultaneous with, or following step (a), bringing into contact the binding guide conjugates and one or more half circle probes, wherein each half circle probe comprises a single-stranded DNA molecule comprising two guide complement portions, wherein each guide complement portion is complementary to at least one of the guide oligonucleotides, and

incubating the binding guide conjugates and the half circle probes under conditions that promote hybridization between the guide oligonucleotides and the half circle probes,

(c) following step (b) and prior to, simultaneous with, or following step (a), incubating the binding guide conjugates and half circle probes under conditions that promote ligation of half circle probes to each other, thereby producing one or more amplification target circles, and

(d) following step (c), incubating the binding guide conjugates and amplification target circles under conditions that promote replication of the amplification target circles, wherein replication of the amplification target circles results in the formation of tandem sequence DNA.

137. A method comprising:

(a) bringing into contact one or more analyte samples and one or more binding guide conjugates, wherein each binding guide conjugate comprises a specific binding molecule and a guide oligonucleotide, wherein each specific binding molecule interacts directly or indirectly with an analyte in the analyte sample, and

incubating the analyte samples and the binding guide conjugates under conditions that promote interaction of the specific binding molecules and the analytes,

(b) prior to, simultaneous with, or following step (a), bringing into contact the binding guide conjugates and one or more half circle probes, wherein each half circle probe comprises a single-stranded DNA molecule comprising two guide complement portions,

wherein each guide complement portion is complementary to at least one of the guide oligonucleotides, wherein each guide oligonucleotide is complementary to one of the guide complement portions of both half circle probes in a pair of half circle probes, wherein the guide complement portions of the same half circle probe are complementary to two different guide oligonucleotides,

wherein the two different guide oligonucleotides that each are complementary to a different one of the guide complement portions of the same half circle probe constitute a pair of guide oligonucleotides, wherein the binding guide conjugates that comprise the guide oligonucleotides in a pair of guide oligonucleotides constitute a pair of binding guide conjugates,

wherein one guide complement portion of each half circle probe in a pair of half circle probes is complementary to one of the guide oligonucleotides in a pair of guide oligonucleotides and the other guide complement portion of each half circle probe in the pair of half circle probes is complementary to the other guide oligonucleotide in the pair of guide oligonucleotides,

wherein both half circle probes in a pair of half circle probes are hybridized to both guide oligonucleotides in a pair of guide oligonucleotides, and

incubating the binding guide conjugates and the half circle probes under conditions that promote hybridization between the guide oligonucleotides and the half circle probes,

(c) following step (b) and prior to, simultaneous with, or following step (a), incubating the binding guide conjugates and half circle probes under conditions that promote ligation of half circle probes in pairs of half circle probes to each other, thereby producing one or more amplification target circles.

138. A method comprising:

(a) bringing into contact one or more analyte samples and one or more binding guide conjugates, wherein each binding guide conjugate comprises a specific binding molecule and a guide oligonucleotide, wherein each specific binding molecule interacts directly or indirectly with an analyte in the analyte sample, and

incubating the analyte samples and the binding guide conjugates under conditions that promote interaction of the specific binding molecules and the analytes,

(b) prior to, simultaneous with, or following step (a), bringing into contact the binding guide conjugates and one or more half circle probes, wherein each half circle probe comprises a single-stranded DNA molecule comprising two guide complement portions, wherein each guide complement portion is complementary to at least one of the guide oligonucleotides, and

incubating the binding guide conjugates and the half circle probes under conditions that promote hybridization between the guide oligonucleotides and the half circle probes,

(c) following steps (a) and (b), incubating the binding guide conjugates and half circle probes under conditions that promote ligation of half circle probes to each other, thereby producing one or more amplification target circles.